Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2013
Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00991081 (Exploratory/Developmental Study of Pharmacogenetic Smoking Cessation Therapy.), which is not on this map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory/Developmental Study of Pharmacogenetic Smoking Cessation Therapy.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Interventions to increase adherence to medications for tobacco dependence.The Cochrane database of systematic reviews · 2019Pooled it
- Biomedical risk assessment as an aid for smoking cessation.The Cochrane database of systematic reviews · 2019Pooled it
- Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.The Cochrane database of systematic reviews · 2017Pooled it
- Postdischarge smoking cessation in subgroups of hospitalized smokers: A latent class analysis.Substance abuseTrial
- Pathways to precision medicine in smoking cessation treatments.Neuroscience letters · 2018Review
- Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Review
- Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature.BMJ open · 2016Article
- Smoking at the workplace: Effects of genetic and environmental causal accounts on attitudes towards smoking employees and restrictive policies.New genetics and society · 2014Article
- Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.Addiction science & clinical practice · 2014Review
- Practical challenges in integrating genomic data into the electronic health record.Genetics in medicine : official journal of the American College of Medical Genetics · 2013Review
- Biomarkers for smoking cessation.Clinical pharmacology and therapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
introductionThere is increasing evidence that response to pharmacological treatment for nicotine dependence may be moderated by genetic polymorphisms. However, the feasibility, acceptability, and impact of genetically tailoring treatment in real-world clinical settings are unknown.
methodsWe conducted a multiphased, mixed-methods feasibility study with current smokers to develop and evaluate a patient-centered, theoretically grounded personalized medicine treatment protocol. The initial research phase included formative work to develop intervention materials. The second phase included a randomized pilot trial to evaluate the intervention. Trial participants (n = 36) were genotyped for ANKK1 rs1800497 and were randomized to receive genetic feedback (GF) plus standard behavioral counseling (BC) for smoking cessation or BC without GF. All participants received genetically tailored pharmacotherapy (nicotine patch or bupropion).
resultsThe intervention was feasible to implement and was acceptable to participants based on satisfaction ratings and objective measures of participation. There was no evidence that the GF resulted in adverse psychological outcomes (e.g., depression, fatalism, reduced perceived control over quitting, differential motivation for quitting) based on quantitative or qualitative outcomes.
conclusionsStudy results suggest that it is feasible to offer treatment within a health care setting that includes genetically tailored pharmacotherapy and doing so had no apparent adverse psychological impacts. Further evaluation of pharmacogenetically tailored smoking cessation interventions appears warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.